This article is more than 5 years old. Information may no longer be current.
Anecortave acetate ‘statistically superior’ to placebo for CNV at 6 months
Click Here to Manage Email Alerts
NEW YORK — A single treatment of anecortave acetate 15 mg was statistically superior to placebo treatment for maintenance of vision and inhibition of lesion growth, according to interim results of a study in choroidal neovascularization.
Jason S. Slakter, MD, who spoke here at the Eleventh Annual Ocular Surgery News New York Symposium on Cataract, Glaucoma, Retina and Refractive Surgery, presented interim 6-month results of two trials in which anecortave acetate is being evaluated for use in choroidal neovascularization (CNV).
He said a second study shows a “trend” favoring the combination of a single treatment of anecortave acetate with photodynamic therapy over PDT alone for maintenance of vision and inhibition of lesion growth at the 6-month follow-up point.
Dr. Slakter said that when the 6-month data were compared from these two studies, there was “no apparent clinical advantage” in the use of PDT followed by anecortave acetate over anecortave acetate treatment alone.
A phase 3 trial has been initiated to compare the clinical efficacy of anecortave acetate 15 mg to PDT in patients with predominantly classic subfoveal choroidal neovascularization, Dr. Slakter said.